ERBB2 and breast carcinoma: Hence, we conducted this single-center retrospective study to investigate the association of baseline MLR, NLR, and PLR with pCR in HER2-positive breast cancer treated with trastuzumab- or trastuzumab plus pertuzumab-based neoadjuvant therapy.